BI 3034701
BI3034701 · Boehringer Ingelheim / Gubra
An investigational triple receptor agonist targeting GLP-1, GIP and NPY2 receptors.
Results availability
No numerical study results are currently summarized for this profile. The development stage and linked studies are listed below.
Mechanism at a glance
Obesity stage by formulation
Latest: Boehringer Ingelheim initiated a Phase 2 obesity study in July 2026; Gubra originated the candidate.
Next: Dose-finding study results; no readout timing is posted.
Clinical study records
Obesity and weight-management studies appear first. Related-condition trials follow by phase, with focus labels to show what each study evaluates. Study stage and results reporting are listed separately. Results summarized above are identified as peer-reviewed or sponsor reported. Otherwise, the label states whether results were posted to a registry or reported in the linked source.
Obesity and weight-management studies
Phase 2 studies1 record
NCT07662122 · Phase 2 dose finding
Weight managementSubcutaneous dose-finding study in adults living with overweight or obesity; the study is designed to assess efficacy and safety.
